Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $141,494.34 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $141,494.34. Following the transaction, the insider directly owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. The trade was a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.01, for a total value of $133,494.66.
• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $133,827.98.

Xeris Biopharma Stock Up 0.1%

Shares of NASDAQ:XERS opened at $8.59 on Friday. The firm has a market capitalization of $1.57 billion, a PE ratio of -78.09 and a beta of 0.70. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The firm’s 50-day moving average is $8.39 and its two-hundred day moving average is $6.97.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on XERS shares. Barclays increased their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. BlackRock Inc. purchased a new stake in Xeris Biopharma during the 2nd quarter worth about $115,042,000. Legal & General Group Plc purchased a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $15,941,000. Parkman Healthcare Partners LLC purchased a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $14,316,000. UBS Group AG raised its position in shares of Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $11,065,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.